In recent years, a number of studies using high-throughput next-generation sequencing (NGS) technologies have revealed numerous gene variants (e.g., KRAS, NRAS, FAM46C, DIS3 and TP53) [7] and have provided a better understanding of the identity and composition of SVs that make up the genomes of newly diagnosed and relapsed MM [8,9]. Here, TP53 is linked to Miyoshi myopathy.